Burgard M, Sansonetti P, Vittecoq D, Descamps P, Guetard D, Herson S, Rozenbaum W, Rouzioux C
Laboratoire de Microbiologie, Hôpital Necker, Paris, France.
AIDS. 1989 Oct;3(10):665-8. doi: 10.1097/00002030-198910000-00009.
A randomized study of 12 treated patients and seven controls was conducted in order to evaluate HPA-23 anti-HIV activity in HIV-infected patients. The antiviral activity was assessed by determining HIV p24 antigenemia. A persistence or even increase in antigenemia was shown in treated patients and thrombocytopenia was observed in nine out of the 12 patients. This suggests that HPA-23 should not be used in anti-HIV therapy.
为评估HPA - 23对HIV感染患者的抗HIV活性，对12例接受治疗的患者和7例对照进行了一项随机研究。通过测定HIV p24抗原血症来评估抗病毒活性。接受治疗的患者出现抗原血症持续甚至增加的情况，并且在12例患者中有9例观察到血小板减少。这表明HPA - 23不应被用于抗HIV治疗。
